Cardiomyopathy Trial, Recruiting NCT05332691 Sponsor: Xiang Wei Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT05332691
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a significant blockage of blood flow leaving the heart (either at rest or when triggered), along with a notably thickened heart wall, as measured by specific medical tests.
  • People whose heart function has been rated as moderately reduced or worse according to a standard medical classification system (confirm with trial site).
  • People whose symptoms have not improved with medications, or who cannot tolerate the medications used to treat their condition.
  • People who have been fully informed about the trial, agree to take part in all required activities, and have signed a consent form.

Who may not be able to join:

  • People who are pregnant.
  • People who also have problems with their heart valves or blocked heart arteries that would require open-heart surgery.
  • People with severe heart failure where the heart's pumping strength is significantly reduced (below a certain measured level).
  • People whose life expectancy is estimated to be less than 12 months.
  • People who are unlikely to follow the trial's required schedule or instructions.
  • People who, in the judgment of the medical team and researchers, are considered unsuitable to take part for any other reason (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiang Wei, M.D., Tongji Hospital

Phone: +8613995525956

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xiang Wei
Registry
ClinicalTrials.gov
Start date
15 April 2022
Est. completion
30 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

All-cause mortality; Procedural success

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov